专注于帕金森氏症的Serina Therapeutics与Element Injects达成合作伙伴关系

2024-05-15 20:26

Enable Injections and Serina Therapeutics (NYSE:SER) Wednesday announced a partnership to develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuse for the treatment of Parkinson’s disease.
SER-252 is an investigational apomorphine therapy developed with Serina’s (SER) POZ platform and designed to provide continuous dopaminergic stimulation.
CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease, the company said.
Preclinical studies support the potential of SER-252 to provide CDS without skin reactions. Serina (SER) plans to advance SER-252 to clinical testing in 2025, it said.
Enable is currently working with a number of pharmaceutical partners to conduct clinical trials and plan for joint commercial launch of their therapies in combination with the enFuse technology.
Under the terms of the agreement, Serina (SER) will obtain a worldwide, exclusive license to the enFuse platform for an upfront and future milestone payments. Enable will also be entitled to product sales and single digit royalties.
Source: Press Release

More on AgeX Therapeutics